VANCOUVER, British Columbia, April 12, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV) a specialty pharmaceutical company is pleased to announce that has completed the final formulation of its lead therapeutics drug, X-Excite for the upcoming clinical trials in the United States. Results of the interim clinical trials in Europe showed X-Excite to appear in the blood rapidly and stay for longer time than the brand, Viagra®. It is believed the longer presence of the drug in the blood may contribute to both buccal (sublingual) absorption and the gastric absorption. For North American trials, the Company has modified the formulation slightly to give the maximal buccal absorption.
"We are very pleased with the results of our European clinical trials. Now we have fine tuned our formulation for the North American clinical trials. With the final formulation, we can now contract out the GMP manufacturing of the drug to a qualified Contract Manufacturing Organization (CMO) and initiate the clinical trials soon after having the drug on hand," said Dr. Hassan Salari, President & CEO of Global Health.
About Sublingual Technology The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver break down. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection. The technology is tested against 40 major drugs and all can benefit from it.
About Global Health Ventures (OTCBB:GHLV) is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies. For more information visit http://www.globalhealth3000.com/
Notice Regarding Forward Looking Statements -This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.
CONTACT: For Investor Relations Contact: Mrs. Kelly Black Premier Media Service Inc (480) 649-8224 or 866 216-8814 email@example.com